Royal Bank of Canada
CTKB icon

Royal Bank of Canada’s Cytek Biosciences CTKB Stock Holding History

Royal Bank of Canada’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19K Buy
4,375
+2,076
+90% +$8.86K ﹤0.01% 6358
2026
Q1 		$10K Sell
2,299
-3,226
-58% -$15.2K ﹤0.01% 6152
2025
Q4 		$28K Buy
5,525
+1,403
+34% +$6.51K ﹤0.01% 5859
2025
Q3 		$15K Sell
4,122
-18,326
-82% -$68.8K ﹤0.01% 6336
2025
Q2 		$76K Buy
22,448
+2,991
+15% +$9.97K ﹤0.01% 5741
2025
Q1 		$78K Sell
19,457
-4,074
-17% -$21.1K ﹤0.01% 5352
2024
Q4 		$152K Buy
23,531
+11,343
+93% +$67.6K ﹤0.01% 5042
2024
Q3 		$68K Buy
12,188
+771
+7% +$4.37K ﹤0.01% 5556
2024
Q2 		$64K Buy
11,417
+7,203
+171% +$43.3K ﹤0.01% 5527
2024
Q1 		$28K Sell
4,214
-36,484
-90% -$289K ﹤0.01% 5772
2023
Q4 		$371K Buy
40,698
+25,140
+162% +$158K ﹤0.01% 4539
2023
Q3 		$86K Buy
15,558
+8,036
+107% +$64.5K ﹤0.01% 5475
2023
Q2 		$64K Buy
7,522
+1,078
+17% +$9.67K ﹤0.01% 5648
2023
Q1 		$60K Sell
6,444
-14,221
-69% -$153K ﹤0.01% 5523
2022
Q4 		$212K Buy
20,665
+18,591
+896% +$250K ﹤0.01% 4824
2022
Q3 		$30K Buy
2,074
+1,430
+222% +$18.6K ﹤0.01% 5975
2022
Q2 		$7K Sell
644
-5,351
-89% -$53.3K ﹤0.01% 6511
2022
Q1 		$65K Buy
5,995
+2,341
+64% +$31.6K ﹤0.01% 5918
2021
Q4 		$59K Buy
3,654
+1,811
+98% +$37.9K ﹤0.01% 6278
2021
Q3 		$40K Buy
+1,843
New +$43.4K ﹤0.01% 6289

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada's CTKB Position: Q2 2026 in Review

Royal Bank of Canada increased its Cytek Biosciences (CTKB) stake by 90% in Q2 2026, buying an estimated $8.86K and bringing the position to 4,375 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #6358.

Royal Bank of Canada first reported a position in CTKB in Q3 2021 and has held it in 20 quarters since. The position peaked at $371K in Q4 2023. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Royal Bank of Canada held 4,375 shares of Cytek Biosciences worth $19K as of Q2 2026.
  • Royal Bank of Canada bought 2,076 Cytek Biosciences shares in Q2 2026, an estimated $8.86K.
  • Cytek Biosciences made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #6358 holding.
  • Royal Bank of Canada first reported a position in Cytek Biosciences in Q3 2021 and has held it in 20 quarters since.
  • Royal Bank of Canada's Cytek Biosciences position peaked at $371K in Q4 2023.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.